Services

Histology

Pharmacology

Medical Device Testing

In Vitro Screening

Animal Model Development

Custom Assay Development

Vivarium Rental

Toxicology

Species

Non-human Primates

Dogs

Mini-pigs / Pigs

Rabbits

Mice

Rats

Sheep

Guinea Pigs

Hamsters

Other Species

Therapeutic Areas

Oncology

Immunology & Inflammation

Neurology / CNS

Cardiovascular

Dermatology & Wound Healing

Metabolism

Gastroenterology

Hepatology

Pulmonology

Infectious Diseases & Sepsis

Musculoskeletal

Nephrology & Urology

Capabilities

GLP / IND-Enabling Studies

Small and Large Animal Housing

Bioanalytical Platforms

About

News

Contact

Career

Request a Quote

Logo
☰
  • Services ⌄
    • Histology
    • Pharmacology
    • Medical Device Testing
    • In Vitro Screening
    • Animal Model Development
    • Custom Assay Development
    • Vivarium Rental
    • Toxicology
  • Species ⌄
    • Non-human Primates
    • Dogs
    • Mini-pigs / Pigs
    • Rabbits
    • Mice
    • Rats
    • Sheep
    • Guinea Pigs
    • Hamsters
    • Other Species
  • Therapeutic Areas ⌄
    • Oncology
    • Immunology & Inflammation
    • Neurology / CNS
    • Cardiovascular
    • Dermatology & Wound Healing
    • Metabolism
    • Gastroenterology
    • Hepatology
    • Pulmonology
    • Infectious Diseases & Sepsis
    • Musculoskeletal
    • Nephrology & Urology
  • Capabilities ⌄
    • GLP / IND-Enabling Studies
    • Small and Large Animal Housing
    • Bioanalytical Platforms
  • About ⌄
    • News
  • Contact ⌄
    • Career
    • Request a Quote

How This CRISPR Biotech Could Make Investors Rich

  • Post author:Sam
  • Post published:December 26, 2017
  • Post category:BioPharma

A look at a biotech company that represents a solid trend in the industry. Source: BioSpace

Continue ReadingHow This CRISPR Biotech Could Make Investors Rich

Array Biopharma Spun Off Heart Drug R&D Into New Subsidiary Yarra Therapeutics

  • Post author:Sam
  • Post published:December 26, 2017
  • Post category:BioPharma

It appears that what Array is trying to do is focus on oncology while the new subsidiary focuses on rare diseases. Source: BioSpace

Continue ReadingArray Biopharma Spun Off Heart Drug R&D Into New Subsidiary Yarra Therapeutics

The Number 1 Small-Cap Biotech Investors are Missing Out On

  • Post author:Sam
  • Post published:December 26, 2017
  • Post category:BioPharma

A look at a small-cap biotech company that investors should consider. Source: BioSpace

Continue ReadingThe Number 1 Small-Cap Biotech Investors are Missing Out On

Mallinckrodt Takes Out Sucampo in Surprising $1.2B Deal

  • Post author:Sam
  • Post published:December 26, 2017
  • Post category:BioPharma

Mallinckrodt picks up Sucampo’s Amitiza as well as two other pipeline compounds. Source: BioSpace

Continue ReadingMallinckrodt Takes Out Sucampo in Surprising $1.2B Deal

Maryland's Precision Medicine Group Lands $275M

  • Post author:Sam
  • Post published:December 26, 2017
  • Post category:BioPharma

The round was led by Berkshire Partners and TPG Growth, with participation from its co-founders and management team, as well as original investors Oak Investment Partners and J.H. Whitney. Source:…

Continue ReadingMaryland's Precision Medicine Group Lands $275M

SoCal's Peregrine Names a New CEO, to Change Name to Avid Bioservices

  • Post author:Sam
  • Post published:December 26, 2017
  • Post category:BioPharma

Dr. Lias succeeds Steven W. King, who resigned as president and chief executive officer of Peregrine to pursue other professional interests. Source: BioSpace

Continue ReadingSoCal's Peregrine Names a New CEO, to Change Name to Avid Bioservices

Celgene Crashed After Follicular Lymphoma Regimen Failed Phase III

  • Post author:Sam
  • Post published:December 21, 2017
  • Post category:BioPharma

Celgene announced the Phase III results late Thursday and share prices dropped about 4 percent to $102.69 as of 9:30 this morning. Source: BioSpace

Continue ReadingCelgene Crashed After Follicular Lymphoma Regimen Failed Phase III

North Carolina Sues Insys Accused of Bribing Doctors to Prescribe Powerful Opioid Spray

  • Post author:Sam
  • Post published:December 21, 2017
  • Post category:BioPharma

North Carolina sued Insys on Thursday, accusing the pharmaceutical company of illegally pushing a powerful fentanyl-based cancer pain medicine called Subsys to boost profits amid the U.S. opioid epidemic. Source:…

Continue ReadingNorth Carolina Sues Insys Accused of Bribing Doctors to Prescribe Powerful Opioid Spray

9 Reasons to Buy Pfizer in 2018 and 1 Big One Not To

  • Post author:Sam
  • Post published:December 21, 2017
  • Post category:BioPharma

Pfizer may be the surprise strong-growth stock for next year. Source: BioSpace

Continue Reading9 Reasons to Buy Pfizer in 2018 and 1 Big One Not To

Biocon's Biosimilar Arm May Raise $500M to Fund Clinical Development

  • Post author:Sam
  • Post published:December 21, 2017
  • Post category:BioPharma

Biotechnology major BioCon is likely to take its group entity Biocon Biologics public and is expected to raise about $500M. Source: BioSpace

Continue ReadingBiocon's Biosimilar Arm May Raise $500M to Fund Clinical Development
  • Go to the previous page
  • 1
  • …
  • 48
  • 49
  • 50
  • 51
  • 52
  • 53
  • 54
  • …
  • 288
  • Go to the next page

Stay Connected

Keep up with the latest news & insights.

Contact Us

Phone:
+1 858-605-5882
Fax:
+1 858-605-5916
Email:
info@biolegacyresearch.com
Mail:

6042 Cornerstone Court W

Suite E

San Diego, CA 92121

Social:
© 2025 BioLegacy Research. All rights reserved.